Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

After Recall, FDA Investigates the Presence of Impurities in Valsartan Products

By The U.S. Food & Drug Administration | October 8, 2018

FDA continues to investigate the presence of impurities in valsartan products and other angiotensin II receptor blockers (ARBs) used to treat high blood pressure and heart failure. FDA recently identified the impurities N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) in certain valsartan products. FDA is posting its test results showing NDMA levels in recalled valsartan products. FDA will also post test results and an assessment of the cancer risk from NDEA when they are available.

The table below shows the NDMA test results for the recalled valsartan products. The analyses reflect average levels of NDMA present in a single tablet based on the strength of the tested drug product within the lots tested, which are identified in the table. Some of products listed below may have been repackaged by other companies as noted in FDA’s list of valsartan products under recall. For reference, consuming up to 0.096 micrograms of NDMA per day is considered reasonably safe for human ingestion based on lifetime exposure.

FDA previously estimated that if 8,000 people took the highest valsartan dose (320 mg) containing NDMA from the recalled batches daily for four years, there may be one additional case of cancer over the lifetimes of the 8,000 people. That estimate was based on the highest daily dose, however many people may have taken lower doses, and therefore their risks would theoretically be less. FDA expects the actual cancer risk to most consumers to be lower than our estimate.

Company Product (tablets) Lots Tested NDMA level (micrograms -mcg/tablet) 
Hetero Labs Ltd Valsartan 320mg VLS18049, VLS18051, VLS18050 0.3-0.4
Prinston Pharmaceutical Valsartan 320mg/HCTZ 25mg 611B18025, 611B18026, 611B18027 13-20
Prinston Pharmaceutical Valsartan 320mg 344B18027, 344B18028, 344B18029 15-16
Teva Pharmaceuticals Valsartan 320mg 1240425A, 1247282M, 1263943A 8-17
Teva Pharmaceuticals Valsartan 320mg/HCTZ 25mg 1217576M, 1217577M, 1217578M 7-10
Torrent Pharmaceuticals Amlodipine 10mg/Valsartan 320 mg/HCTZ 25mg BBX2E001, BBX2E002, BBX2E003 10-12
Torrent Pharmaceuticals Amlodipine 10mg/Valsartan 320 mg BV77E001, BV77E002, BV77E003 5-9
Torrent Pharmaceuticals Valsartan 320mg BV48D001, BV48D002 0.5-0.6

(Source: The U.S. Food & Drug Administration)

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE